ARTICLE | Clinical News
Bremelanotide: Ph III data
November 11, 2016 7:38 PM UTC
Top-line data from a total of 1,202 premenopausal women with HSDD in the modified intent-to-treat (mITT) populations of the identical, 24-week, double-blind, U.S. and Canadian Phase III Reconnect Stud...
BCIQ Target Profiles